Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-075-4 | CAS number: 78-00-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Repeated dose toxicity: other routes
Administrative data
- Endpoint:
- short-term repeated dose toxicity: other route
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 978
Materials and methods
- Principles of method if other than guideline:
- Study well documented, meets generally accepted scientific principles, acceptable for assessment
- GLP compliance:
- not specified
Test material
- Reference substance name:
- Tetraethyllead
- EC Number:
- 201-075-4
- EC Name:
- Tetraethyllead
- Cas Number:
- 78-00-2
- Molecular formula:
- C8H20Pb
- IUPAC Name:
- tetraethylplumbane
Constituent 1
Test animals
- Species:
- monkey
- Strain:
- other: Rhesus
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- 3 groups of 2 male and 2 female
Administration / exposure
- Route of administration:
- intravenous
- Vehicle:
- ethanol
- Details on exposure:
- 0.6 - 1.2 mg/ kg/ day
- Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- Low dose: 14 days. High dose: 7 days.
- Frequency of treatment:
- daily
Doses / concentrations
- Remarks:
- Doses / Concentrations:
Low dose: 0.6 mg/kg/bw/day for 7 days, then 1.2mg/kg/bw/day for 7 days. High dose: 6.0mg/kg/bw/day for 7 days.
- No. of animals per sex per dose:
- 2
- Control animals:
- yes
- Details on study design:
- Post-exposure period: 28 days
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- In the high dose group, three out of four animals died.
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- In the high dose group, three out of four animals died.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Symptoms in high dose animals included reduced body weight
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- Symptoms in high dose animals included reduced food intake
- Food efficiency:
- effects observed, treatment-related
- Description (incidence and severity):
- Symptoms in high dose animals included
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- In the high dose group included lowered brain cholesterinase and increased serum urea, serum bilrubin and glycosuria. No clinico-chemical findings were observed in the low dose group.
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- In the high dose group, pathological findings included degeneration of the peripheral neuraxons and muscle fibre
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- For the low dose group
- Histopathological findings: neoplastic:
- no effects observed
- Description (incidence and severity):
- For the low dose group
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- 0.6 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
In low dose animals no abnormal symptoms were detected.
Symptoms in high dose animals included gastro-intestinal disturbances, pathological reflexes, muscle tremor, and
reduced food intake and body weight.
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
